Last reviewed · How we verify
NCT06309459
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma
trial testing Carbonic anhydrase staining levels in Triple Negative Breast Cancer in 40 participants. Completed in 1 May 2023.
1 May 2023
Quick facts
| Lead sponsor | Kahramanmaras Sutcu Imam University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 August 2018 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Carbonic anhydrase staining levels
Conditions studied
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
- Carbonic Anhydrase IX — all drugs for Carbonic Anhydrase IX →
Sponsor
Kahramanmaras Sutcu Imam University
Who can join
18 and older, any sex, with Triple Negative Breast Cancer or Carbonic Anhydrase IX. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06309459
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Triple Negative Breast Cancer
Currently open trials in the same condition.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
Other Kahramanmaras Sutcu Imam University trials
Trials by the same sponsor.
- NCT07511322 — Enteral Nutrition Education Provided Using the Pecha Kucha Method · enrolling by invitation
- NCT07515287 — Restoration of Sensorimotor Function in Middle-Aged Women With Chronic Lumbar Disc Herniation: The Effect of Pilates on · NA · enrolling by invitation
- NCT07451691 — The Effect of the World Health Organisation-Based Intrapartum Care Model on Labour Pain, Comfort, Satisfaction and Postp · NA · not yet recruiting
- NCT07471412 — Sexually Transmitted Infections in Migrant Women · NA · not yet recruiting
- NCT07332065 — The Effects of Mandala Coloring on Women During Menopause · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06309459 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kahramanmaras Sutcu Imam University
- Last refreshed: 13 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309459.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing